Sterling Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$133K Sell
264
-25
-9% -$13.2K ﹤0.01% 1307
2026
Q2
$155K Buy
289
+76
+36% +$38.9K ﹤0.01% 1282
2026
Q1
$111K Buy
213
+91
+75% +$43.5K ﹤0.01% 1362
2025
Q4
$71K Buy
122
+77
+171% +$39.3K ﹤0.01% 1661
2025
Q3
$20.6K Buy
45
+4
+10% +$1.49K ﹤0.01% 2121
2025
Q2
$12.4K Buy
41
+22
+116% +$6.56K ﹤0.01% 1993
2025
Q1
$6.29K Buy
19
+1
+6% +$329 ﹤0.01% 2042
2024
Q4
$5.55K Hold
18
– – ﹤0.01% 2432
2024
Q3
$3.82K Buy
+18
New +$4.6K ﹤0.01% 1867

Other funds holding MDGL

Sterling Capital Management's MDGL Position: Q3 2026 in Review

Sterling Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 8.7% in Q3 2026, selling an estimated $13.2K and leaving 264 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #1307.

Sterling Capital Management first reported a position in MDGL in Q3 2024 and has held it in 9 quarters since. The position peaked at $155K in Q2 2026. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Sterling Capital Management held 264 shares of Madrigal Pharmaceuticals worth $133K as of Q3 2026.
  • Sterling Capital Management sold 25 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $13.2K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1307 holding.
  • Sterling Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Madrigal Pharmaceuticals position peaked at $155K in Q2 2026.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.